Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Bullboard Posts
Comment by polo11on Dec 03, 2016 1:37pm
78 Views
Post# 25550717

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:how much will PP be ?

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:how much will PP be ?

TORONTO, ONTARIO--(Marketwired - Sept. 6, 2016) -

Rupert Resources Ltd. ("Rupert" or the "Company") (TSX VENTURE:RUP) is pleased to announce that it has completed its previously announced non-brokered private placement of convertible debentures ("Convertible Debentures") for gross proceeds of CAD$7,707,500 (the "Private Placement").
"The Company thanks its supportive investors, will now turn its focus to completing the acquisition of the permitted Pahtavaara gold mine and is pleased to announce resumption of exploration drilling," said Brian Hinchcliffe, President and CEO of the Company.

Private Placement

The Convertible Debentures have a 36 month maturity date and bear an interest rate of 5% per annum, payable on a semi-annual basis. The Convertible Debentures are secured against the general assets of the Company.

Each Convertible Debenture will be convertible into common shares of the Company ("Common Shares") at the option of the holder prior to maturity, at a price of CAD$0.95 per Common Share (the "Conversion Price"). The Convertible Debentures have typical adjustment provisions.
After 12 months after the issue date of the Convertible Debentures, the Company has the option to repay the principal amount of the Convertible Debentures in Common Shares provided certain circumstances are met, including that the 30 trading day volume weighted average price of the Common Shares is equal to or greater than 170% of the Conversion Price.

The proceeds from the Private Placement will be used for the exploration and development required to assist in returning the Pahtavaara gold mine to production.

The securities issued in connection with the Private Placement will be subject to a four-month hold period, in accordance with applicable securities laws.

 


Bullboard Posts